Artificial Intelligence in Drug Discovery

Introduction Bringing a new drug to market traditionally takes over a decade and costs billions, involving stages from discovery to regulatory approval. Artificial intelligence (AI)–utilizing machine learning, deep learning, natural-language processing (NLP), and generative modeling–is now revolutionizing this process by automating and accelerating critical steps, reducing time and expense while enhancing predictive power.[1] Artificial Intelligence Across Drug Discovery Stages[1] Target identification and validation: AI analyzes genomics, proteomics, and clinical data to pinpoint disease-related proteins or genes[1] Hit identification: Neural-net-driven virtual screening evaluates millions of compounds in silico to find potential binders[1] Lead optimization: Generative AI (generative adversarial networks, reinforcement learning) refines molecules simultaneously for efficacy, safety, and drug-like properties[1] Preclinical testing: Predictive models estimate absorption, distribution, metabolism, excretion, toxicity profiles ahead of costly experiments[1] Clinical trials: AI identifies eligible patients through electronic health record (EHR) mining and simulates control arms (“digital twins”) to speed recruitment and optimize trial design[1] Regulatory and safety monitoring: AI enhances pharmacovigilance by analyzing real-world data for adverse events.[1] Artificial Intelligence Tools Driving Discovery[1,2] IBM Watson, BenevolentAI: Perform NLP-based literature and data mining[1] AlphaFold: Accurately predicts three-dimensional protein structures[1] AtomNet (Atomwise), PyRx, Schrödinger LiveDesign: Enable AI-enhanced docking and virtual screening[1] DeepChem, DeepGenomics, Insilico Medicine, Reinvent, AIDDISON™: Support QSAR modeling, mutation impact prediction, fragment-based and de novo design, and multi-criteria optimization[1] Tox21, Lhasa: Provide toxicity and metabolism prediction tools[1] SYNTHIA™, Chemputer: Automate synthesis planning and execution (e.g., Chemputer synthesized FDA–approved molecules with human-comparable yields).[1] E.g., Nytol, rufinamide, and sildenafil were synthesized using a chemputer without any human interaction, and with yields comparable to or better than those achieved manually[2] Deep 6 AI, Unlearn AI, Tempus, PathAI, GNS Healthcare: Deploy AI for patient recruitment, digital control arms, genomic-informed therapy selection, precise diagnostics, and response prediction.[1] Milestone Artificial Intelligence–Discovered Drugs[1] Rentosertib (ISM001–055)[3] Discovered by Insilico Medicine using AI platforms (PandaOmics and Chemistry42) to identify both the target (TNIK) and molecule[3] In March 2025, granted first AI–designed-drug generic name by the USAN Council[3] Phase IIa trial in 71 idiopathic pulmonary fibrosis (IPF) patients showed +98.4 mL improvement in forced vital capacity versus −20.3 mL decline in placebo over 12 weeks; biomarker analyses (COL1A1, MMP10, FAP down; IL–10 up) validated mechanism[3] From 2021 to 2024, Insilico nominated 22 preclinical candidates in 12–18 months each–significantly aligning with preclinical timelines and demonstrating 100% progression to IND-enabling studies[3] Now advancing to larger Phase IIb/III trials following regulatory engagements.[3] Halicin[1] Identified by MIT’s Jameel Clinic (Collins, Barzilay, Stokes) via deep learning, screening 2500 training molecules and 6000 from the Broad Drug Repurposing Hub[1] Demonstrated broad-spectrum antibiotic activity–effective against Clostridioides difficile, Acinetobacter baumannii, Mycobacterium tuberculosis, and Escherichia coliin vitro–and cleared infections in mouse models within 24 h[1] Unique mechanism: Disrupts bacterial electrochemical gradients, a low-resistance path for bacteria. Bacteria didn’t develop resistance after 30 days, in contrast to ciprofloxacin[1] QSAR-designed BACE1 inhibitors (Alzheimer’s)[1] Secondary metabolite prediction for natural product antibiotics[1] COVID-19 efforts: AI is being used for epitope prediction, drug repurposing against SARS-CoV-2, and generative design of new binders.[1] These approaches align with emerging 2023 ethical guidelines for AI in healthcare (e.g., ICMR), emphasizing oversight and transparency.Outlook and Conclusion AI tools–from virtual screening to generative design and synthetic automation–are reshaping drug discovery. Success stories such as rentosertib and halicin show the potential of AI not just to supplement, but to originate clinically meaningful drugs. Despite challenges around data, interpretability, regulatory alignment, and costs, structured frameworks and human oversight can help overcome them. As AI matures and integrates seamlessly into workflows, drug development can become faster, cheaper, safer, and more personalized–ultimately delivering better outcomes for patients worldwide.